Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERFECT: Intramyocardial transplantation of CD133+ bone marrow stem cells during CABG
DRKS00000213Phase 3Terminated
- Sponsor
- Miltenyi Biotec
- Start
- Sep 2009
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of autologous CD133+ cells in coronary arteriosclerosis and myocardial infarction (MI) (2 arms), sponsored by Miltenyi Biotec. Started Sep 2009; status: terminated.
02
Drugs
autologous CD133+ cells
03
Conditions
coronary arteriosclerosismyocardial infarction (MI)
Beyond the preview
Go deeper on DRKS00000213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00000213.